Tamiflu Reduces Flu Complications and Patients Get Back on Their Feet Faster

Use of antiviral drugs to help treat influenza had been recommended by the Centers for Disease Control and Prevention, earlier this month.

Use of antiviral drugs to help treat influenza had been recommended by the Centers for Disease Control and Prevention, earlier this month. This is the year when the available vaccine is not a good match for the current strain.

Now, new evidence about a popular antiviral-often criticized as ineffective-shows that it can alleviate symptoms and prevent respiratory complications.

Quiz on Flu
Influenza (or rather, the flu) is a cold weather infectious condition that affects the young and old alike. Though most reported cases are mild, the flu can sometimes cause severe and life-threatening complications in both children and adults, thanks to wrong medications and improper vaccinations. Learn more about the disease from our Flu Quiz and guard yourself and your family from a possible infection.

Research by the University of Michigan, the London School of Hygiene and Tropical Medicine and the University of Alabama found that Oseltamivir, marketed as Tamiflu, shortens the duration of symptoms by about one day and reduces by 44 percent respiratory infections that sometimes develop, said study co-author Dr. Arnold Monto, the Thomas Francis Jr. Collegiate Professor of Public Health at the University of Michigan School of Public Health.

"This is the first patient-level analysis of how well this drug works. Previous research has questioned its success and use in light of the side effects of nausea and vomiting, but the other studies combined those infected with influenza and those without, which diluted the positive effect in treatment," Monto said.

Researchers conducted meta-analysis of data from all published and unpublished clinical trials from 1997-2001 to determine effectiveness of the antiviral drug. The trials involved more than 4,300 patients, better than half of whom were treated with Oseltamivir.

Flu Virus Can Spread Up to 6 Feet Above the Patient
The influenza virus can spread to 6 feet from a patient through submicron particles breaking the old thought that it spreads only through coughing and sneezing.

The research, using data made available by Tamiflu manufacturer Roche and analyzed by an independent research group led by Joanna Dobson and Stuart Pocock of the London School of Hygiene and Tropical Medicine, is published in "The Lancet."

Oseltamivir is in a class of drugs known as neuraminidase inhibitors. They block the enzyme activity that occurs in influenza Type A and B viruses. Most of the patients studied had Influenza Type A, with the most prevalent strain reported as H3N2, the same one that is hitting much of the United States this year.

Hib Vaccine - Types, Dosage Schedule, Contraindications and Side Effects
The Hib vaccine protects children against infections like meningitis and pneumonia that are caused by the Haemophilus influenzae type b bacterium.

When used at the normal prescribed dosage of 75 mg twice a day for adults, within 36 hours following development of at least two flu symptoms, Oseltamivir was shown to reduce the duration of the illness by 21 percent. With the drug, symptom alleviation occurred, on average, at 98 hours compared with 123 hours with placebo.

The researchers found no benefit in adults who did not have the flu virus, confirming the drug's role as an antiviral.

Effectiveness of Inactivated Influenza Vaccine in Children Aged 9 Months to 3 Years
Researchers studied the effectiveness of trivalent inactivated influenza vaccine against laboratory-confirmed influenza A and B infections in children aged 9 months to 3 years.

In addition to reducing the risk of respiratory tract infections requiring antibiotics, like pneumonia (4.9 percent had complications with the drug compared with 8.7 percent on placebo), Oseltamivir decreased hospital admissions by 63 percent (0.6 percent vs. 1.7 percent).

The researchers also found some of the same complications of the drug noted in previous research, with an increase in nausea (3.7 percent) and vomiting (4.7 percent). They did not find differences between the two groups with respect to development of neurological or psychological disorders that had been raised in previous research.

Source-Newswise